Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,546 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control regimen Clear all
Completed Phase 1 Interventional

Burn Micronutrient Repletion Pilot Study

NCT00879723
View directory record Official record
Conditions
Burn
Interventions
Vitamin and Mineral supplementation
Dietary Supplement
Lead sponsor
Southern Illinois University
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 10, 2026, 4:16 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

NCT03467932
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 10, 2026, 4:16 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

NCT03115567
View directory record Official record
Conditions
Acneiform Rash, Papulopustular Eruption
Interventions
Triamcinolone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 10, 2026, 4:16 AM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers

NCT00330265
View directory record Official record
Conditions
Foot Ulcer, Diabetes
Interventions
KC-002, Conventional Wound Therapy
Device · Other
Lead sponsor
KeraCure
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
21
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2008 · Synced Sep 10, 2026, 4:16 AM EDT
Recruiting Phase 4 Interventional

Nonopioid Pain Control Regimen After Open Reduction and Internal Fixation of Traumatic Fractures

NCT06113211
View directory record Official record
Conditions
Opioid Use, Fractures, Bone, Trauma
Interventions
Narcotic pain medication, Nonnarcotic pain medications
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 10, 2026, 4:16 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

NCT05064878
View directory record Official record
Conditions
CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
Interventions
Fenfluramine, Placebo
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
1 Year to 35 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 10, 2026, 4:16 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional Accepts healthy volunteers

Aerobic Exercise After Traumatic Brain Injury

NCT05786729
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Aerobic Exercise (AER), Rehabilitation
Other
Lead sponsor
Centre for Neuro Skills
Industry
Eligibility
18 Years to 60 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bakersfield, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Sep 10, 2026, 4:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects

NCT04228302
View directory record Official record
Conditions
Healthy Adults
Interventions
EC5026 oral capsule, Placebo oral capsule
Drug · Other
Lead sponsor
EicOsis Human Health Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Sep 10, 2026, 4:16 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 10, 2026, 4:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

NCT05197270
View directory record Official record
Conditions
Neovascular (Wet) Age-Related Macular Degeneration
Interventions
4D-150 IVT, Aflibercept IVT
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
25
States / cities
Phoenix, Arizona • Oxnard, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 10, 2026, 4:16 AM EDT
Terminated Not applicable Interventional

Study to Evaluate Iovera®° in Adult Patients Undergoing Total Knee Arthroplasty

NCT04191031
View directory record Official record
Conditions
Post-Operative Pain Management
Interventions
ioveraº, ioveraº sham
Device
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
22 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Fremont, California • Pasadena, California • Tamarac, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 10, 2026, 4:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers

NCT00336102
View directory record Official record
Conditions
Breast Cancer, Fatigue, Hypothyroidism
Interventions
physiologic testing, fatigue assessment and management, management of therapy complications
Other · Procedure
Lead sponsor
University of South Florida
Other
Eligibility
20 Years to 80 Years · Female only
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
41
States / cities
Phoenix, Arizona • Greeley, Colorado • Loveland, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Sep 10, 2026, 4:16 AM EDT
Completed Phase 2 Interventional Results available

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

NCT03981822
View directory record Official record
Conditions
Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Sexually Transmitted Diseases, Viral, Sexually Transmitted Diseases, Warts
Interventions
VP-102 and applicator, Placebo
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Plainfield, Indiana • Baton Rouge, Louisiana • Clarkston, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 10, 2026, 4:16 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)

NCT00509275
View directory record Official record
Conditions
Tinea Pedis
Interventions
W0027, Placebo
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Louisville, Kentucky • Warren, Michigan • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 10, 2026, 4:16 AM EDT
Not listed Not applicable Interventional

Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory

NCT01157130
View directory record Official record
Conditions
Early Stage Breast Cancer (Stage 0-III)
Interventions
Exercise Regimen
Other
Lead sponsor
Nevada Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 10, 2026, 4:16 AM EDT
Not yet recruiting Phase 4 Interventional

The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)

NCT07276802
View directory record Official record
Conditions
Post Cataract Surgery
Interventions
Triamcinolone (Optional), control group
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
22 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 10, 2026, 4:16 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT04592419
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
81
States / cities
Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 10, 2026, 4:16 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

NCT01641822
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI, Placebo to match AZLI, Tobramycin inhalation solution
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more
Source: ClinicalTrials.gov public record
Updated May 8, 2016 · Synced Sep 10, 2026, 4:16 AM EDT
Completed Not applicable Interventional

Tablet-Aided BehavioraL Intervention EffecT on Self-management Skills

NCT02128854
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
Interventions
Tablets Intervention
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
45 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 10, 2026, 4:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

New at Parenting Study

NCT07076381
View directory record Official record
Conditions
Control Group, Counseling
Interventions
Brief and solutions-therapy intervention
Behavioral
Lead sponsor
University of San Francisco
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 10, 2026, 4:16 AM EDT
Completed Not applicable Interventional Results available

Intermittent Fasting Adherence and Self Tracking

NCT04836312
View directory record Official record
Conditions
Hypertension, Obesity
Interventions
Soft Commitment Device
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 10, 2026, 4:16 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Natural Versus Programmed Frozen Embryo Transfer (NatPro)

NCT04551807
View directory record Official record
Conditions
Pregnancy Related, Pre-Eclampsia
Interventions
Modified natural cycle, Programmed cycle
Procedure
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
788 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
15
States / cities
San Francisco, California • Sunnyvale, California • Orange, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 10, 2026, 4:16 AM EDT
Terminated Phase 2 Interventional Results available

A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag

NCT03942211
View directory record Official record
Conditions
Sarcoidosis-associated Pulmonary Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 10, 2026, 4:16 AM EDT
Recruiting Not applicable Interventional

Home Based Functional Balance Intervention for Multiple Sclerosis

NCT07355387
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis Acute and Progressive
Interventions
Multicomponent balance intervention consisting of four components including dual-tasking, functional strength, vestibular and dynamic balance., Stretching
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 10, 2026, 4:16 AM EDT